Shanghai Yingrui Biopharma Co.,Ltd.
Home
About Us
ABOUT US
Corporate Culture
Products
APIs & Intermediates
PEG Derivatives
The others
Services
News
Company News
Industry Trends
Contact Us
NEWS CENTER
Intensive landing of domestic innovative gout drugs
With the continuous improvement of living standards, the incidence rate of gout also rises, and presents a younger trend.
2026-09-09
2026
09-09
The sentiment in the pharmaceutical sector is heating up, with pharmaceutical companies recording 6 daily limit ups within 8 trading days
The sentiment in the pharmaceutical sector is heating up.
2026-08-24
08-24
Global biotech financing is experiencing a surge in popularity
Looking back at July 2026, the global biotechnology industry ushered in an intensive financing boom, and the industry's innovative value continued to be recognized by the capital market.
2026-08-10
08-10
Haisco 2026 continues to make innovative breakthroughs, with new progress in the oncology pipeline!
HSK42360-Na is a new chemical drug of Class 1 independently developed by Hisco.
2026-07-22
07-22
The performance of domestic innovative drugs is accelerating
At present, the domestic pharmaceutical innovation field is showing a strong development momentum.
2026-07-09
07-09
Capital will flock to the brain-computer interface field
According to data, the domestic brain-computer field completed 26 rounds of financing with a total scale of 1.778 billion yuan in 2025.
2026-06-25
06-25
Hypertension medication enters a new era of long-acting efficacy
Hypertension is a major global risk factor for cardiovascular diseases, and antihypertensive drugs are chemical or biological agents used for the prevention and treatment of hypertension and related cardiovascular diseases. towards "precision targeting". It is reported that since 2026, various new mechanism drugs have achieved breakthroughs.
2026-06-03
06-03
In May, the enthusiasm for mergers and acquisitions of domestic medical devices surged
Against the backdrop of normalized centralized procurement and accelerated liquidation during the industry downturn, consolidation is emerging as a core keyword in the evolution of China's medical device industry. It is reported that since May 2026, there have been multiple mergers and acquisitions in the Chinese medical device industry, involving companies such as Eastar Medical and Da An Gene
2026-05-19
05-19
The pharmaceutical industry is experiencing a round of structural recovery
The pharmaceutical industry is undergoing a round of structural recovery. Regarding the layout of the innovative drug sector, some analysts point out that, based on the research and judgments of multiple institutions, three main lines can be focused on: innovative drug leaders with global competitiveness, enterprises with technological advantages in specific niches, and supporting links in the industrial chain.
2026-04-30
04-30
In the first quarter, domestic pharmaceutical companies delivered impressive performance
Recently, pharmaceutical companies have been releasing their first-quarter earnings forecasts intensively. Overall, the innovative drug sector has emerged as the absolute mainstay, with over ten pharmaceutical companies reporting positive earnings forecasts, and three even showing a net profit increase of over 900%.
2026-04-17
04-17